Antibodies against transglutaminases, peptidylarginine deiminase and citrulline in rheumatoid arthritis--new pathways to epitope spreading.

Hospital Pharmacy, Malmö University Hospital, Malmö, Sweden.
Clinical and experimental rheumatology (Impact Factor: 2.66). 01/2006; 24(1):12-8.
Source: PubMed

ABSTRACT The findings of the involvement of tissue transglutaminase (tTg) in the pathogenesis of coeliac disease (CD) have stimulated progress in the field of auto-immune diseases. Another calcium-dependent cysteine enzyme, peptidylarginine deiminase type 4 (PAD4), seems to be involved in the pathogenesis of rheumatoid arthritis (RA). There are obvious similarities between Tgs and PADs.
Using enzyme-linked immuno-sorbent assays, we have measured the occurrence of antibodies against guinea pig (gp) and human recombinant (hr) tTg, PAD and citrulline in 59 controls and 184 RA-patients, of whom 71 were treated with methotrexate (mtx).
In addition to the expected antibodies against citrulline (62%), sera from the 113 RA-patients without mtx treatment contained significantly increased frequencies of IgG anti-PAD (35%), IgA anti-gp-tTg (34%), IgA anti-hr tTg (20%), IgG anti-gp-tTg (13%) and IgA anti-hr-FXIII (15%) compared to controls. In sera from the mtx-treated RA-patients the expression of antibodies was reduced. In patients not treated with methotrexate there was a statistically significant correlation between, on one hand, IgG anti-PAD and on the other hand, IgG anti-citrulline, IgA anti-gp-tTg, IgA anti-hr-tTg, IgG anti-gp-tTg, IgG anti-hr-tTg, or IgA anti-hr-FXIII. In the mtx-treated group these correlations were less pronounced.
In addition to the expected antibodies against citrulline, sera from RA-patients contained antibodies against PAD and against Tgs of at least two kinds, indicating that the specificity for anti-tTg in CD is far from complete. Most of the patients displayed more than one antibody, a possible indication of epitope spreading. MTX-treatment reduced the expression of antibodies.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The literature published in the last decade has variously assessed the possible association between coeliac disease (CD) and other chronic inflammatory autoimmune diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and psoriasis (Ps). This study included a total of 93 patients (15 with RA, 27 with PsA and 51 with Ps). None from the group with RA and PsA were positive to the test, while 3 of the patients belonging to the group with Ps tested positive. All three underwent intestinal biopsy, which confirmed the presence of CD. Our data revealed a higher prevalence of CD in patients with Ps compared to the general population: 3:51 patients (5.88%) vs. 1:184 resident (0.54%). It can be affirmed that screening for CD is not routinely recommended for patients suffering from RA and PsA. KeywordsCoeliac disease-Epidemiology-Prevalence-Psoriasis-Psoriatic arthritis-Rheumatoid arthritis
    Mediterranean Journal of Nutrition and Metabolism 3(1):61-64.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To identify new IgG autoantibodies in sera from patients with rheumatoid arthritis (RA). We tested serum samples from 19 patients with RA with given human leukocyte antigen (HLA)-DR genotypes, from 7 patients with spondylarthropathy, 2 patients with lupus, 4 patients with systemic sclerosis and 10 healthy individuals on 8268 human protein arrays. We identified four antigens (peptidyl arginine deiminase 4 (PAD4), protein kinase Cbeta1 (PKCbeta1), phosphatylinositol 4 phosphate 5 kinase type II gamma (PIP4K2C) and v raf murine sarcoma viral oncogene homologue B1 catalytic domain (BRAF)) that were recognised almost uniquely by sera from patients with RA on protein arrays. Using purified proteins, we confirmed that PAD4 and BRAF are recognised almost uniquely by patients with RA. We identified PAD4 and BRAF as RA specific autoantigens.
    Annals of the Rheumatic Diseases 11/2009; 68(4):591-4. · 9.11 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Autoantibodies have been associated with human pathologies for a long time, particularly with autoimmune diseases (AIDs). Rheumatoid factor (RF) is known since the late 1930s to be associated with rheumatoid arthritis (RA). The discovery of anticitrullinated protein antibodies in the last century has changed this and other posttranslational modifications (PTM) relevant to RA have since been described. Such PTM introduce neoepitopes in proteins that can generate novel autoantibody specificities. The recent recognition of these novel specificities in RA provides a unique opportunity to understand human B-cell development in vivo. In this paper, we will review the three of the main classes of PTMs already associated with RA: citrullination, carbamylation, and oxidation. With the advancement of research methodologies it should be expected that other autoantibodies against PTM proteins could be discovered in patients with autoimmune diseases. Many of such autoantibodies may provide significant biomarker potential.
    Mediators of Inflammation 01/2014; 2014:492873. · 3.88 Impact Factor

Full-text (2 Sources)

Available from
May 23, 2014